The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Adhesive Patch of 90 sq. cm. and containing as active ingredient 100 mg. of ketoprofen for the local treatment of traumatic injuries and extra-articular rheumatism More
Novel patent pending in dermatology: combination of a well known topical antibiotic with a topical steroid indicated for skin infections with inflammatory process More
Range of Glucosamine based pharmaceutical products (capsule, tablets,sachets,) authorized in some countries of Europe or ready to register as well as other innovative galenic developments under development. More
Displaying 1..10 of 712 -
per page
Next page
Order by